ENT Medical News about squamous cell carcinoma of the larynx and pharynx;platin-based exclusive chemotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Appropriate Antibiotic Use for Acute Otitis Media

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx
Cancer, 06/30/09

Holsinger FC et al. - In a study to determine the long-term outcomes of pts with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy, it was reported that for selected pts, EC may provide long-term, durable disease control. For pts who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of pts.

Methods

142 who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 yrs or until death.
35 pts had >10 yrs of follow-up.

Results

Survival rates at 1 yr and 5 yrs were 95.8% and 61.2%, respectively.
The main causes of death were metachronous second primary tumors (n=27) and intercurrent disease (n=21).
Death related to EC was not encountered, and only 2 pts (1.4%) had grade 4 toxicity.
In multivariate analysis, primary tumor arising outside the glottic larynx and a Charlson comorbidity index >1 were associated with a statistically significant reduction in survival.
1-yr and 5-yr Kaplan-Meier local control estimates were 76.1% and 50.7%, respectively.
Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in pts who had glottic cancer to 88.7% in pts who had tumor originating from other sites.
Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for successful modulation of local therapy in 54.9% of pts.

<< Previous
Sleep, quality of life, and productivity impact of nasal symptoms...

Next >>
Functional and oncologic results following transoral laser...